Supplemental Table 1 Multivariate analysis of neutrophil and platelet

Transcription

1 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 1 Multivariate analysis of neutrophil and platelet engraftment Variable Neutrophil engraftment* Platelet engraftment HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference RD/1AG-MM-GVH 3.46 ( ) < ( ) <01 0 reference 0 reference RD/HLA-A-MM-GVH 4.71 ( ) < ( ) <01 RD/HLA-B-MM-GVH 2.77 ( ) < ( ) 01 RD/HLA-DR-MM-GVH 3.70 ( ) < ( ) <01 *Other significant variables in model A were; diagnosis, AML (reference, 0), ALL (HR, 1.12, 95% CI, , P = 33), CML (HR, 5, 95% CI, , P = 77, MDS (HR, 4, 95% CI, , P = 37); disease risk, standard risk (reference, 0), high risk (HR, 0.79; 95% CI, ; P < 01), status not known, (HR, 7; 95% CI, ; P = 10); year of transplantation, (reference, 0), (HR, 1.15; 95% CI, ; P = 05. Other significant variables in model A were; patient age, (reference, 0), 50- (HR, 0.72, 95% CI, 5-1, P < 01); disease risk, standard risk (reference, 0), high risk (HR, 3; 95% CI, ; P < 01), status not known, (HR, 2; 95% CI, 4-5; P = 0.122); GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 6; 95% CI, ; P = 22), CSA/TAC + steroid/mmf (HR, 6; 95% CI, ; P = 0.527), other/missing (HR, 0.52; 95% CI, ; P=26). 1

2 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 2 Multivariate analysis of acute and chronic GVHD Variable grade II-IV acute GVHD* grade III-IV acute GVHD chronic GVHD extensive chronic GVHD** HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value RD/1AG-MM-GVH 1.64 ( ) < ( ) < ( ) < ( ) <01 RD/HLA-A-MM-GVH 1.52 ( ) ( ) < ( ) ( ) <01 RD/HLA-B-MM-GVH 1.79 ( ) < ( ) < ( ) < ( ) <01 RD/HLA-DR-MM-GVH 1.59 ( ) < ( ) ( ) ( ) <01 *Other significant variables; none Other significant variables in model A were; GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 1.95; 95% CI, ; P < 01), CSA/TAC + steroid/mmf (HR, 1.46; 95% CI, ; P = 28), other/missing (HR, 9; 95% CI, ; P = 0.505). Other significant variables in model A were; patient age, (reference, 0), 50- (HR, 1, 95% CI, , P = 09); sex of recipient, female (reference, 0), male (HR, 1.24; 95% CI, ; P = 04); diagnosis, AML (reference, 0), ALL (HR, 0.97, 95% CI, , P = 0.736), CML (HR, 6, 95% CI, , P = 0.354), MDS (HR, 1.29, 95% CI, , P = 17); year of transplantation, (reference, 0), (HR, 0; 95% CI, ; P = 06). ** Other significant variables in model A were; sex of recipient, female (reference, 0), male (HR, 1.29; 95% CI, ; P = 16); diagnosis, AML (reference, 0), ALL (HR, 0, 95% CI, , P = 0.984), CML (HR, 1.32, 95% CI, , P = 0.176), MDS (HR, 1.49, 95% CI, , P = 07); GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 0.99; 95% CI, ; P = 0.938), CSA/TAC + steroid/mmf (HR, 0.56; 95% CI, ; P = 12), other/missing (HR, 0.17; 95% CI, ; P=82) 2

3 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 3 Cause of death for patients who died without relapse Catetory RD/1AG-MM-GVH Total Graft failure 34 (5%) 2 (1%) GVHD 61 (10%) 32 (18%) IP 32 (5%) 7 (4%) Infection 235 (38%) 46 (26%) Organ failure 117 (19%) 49 (28%) Others 108 (17%) 20 (11%) Unknown 34 (5%) 19 (11%) Total Abbreviations: GVHD, graft-versus-host disease; IP, interstitial pneumonia. 3

4 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 4 Multivariate analysis of acute and chronic GVHD Variable grade II-IV acute GVHD* grade III-IV acute GVHD chronic GVHD extensive chronic GVHD** HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference 0 reference 0 reference RD/1AG-MM-GVH wotdep 1.74 ( ) < ( ) < ( ) < ( ) <01 RD/1AG-MM-GVH wtdep 7 ( ) ( ) ( ) ( ) reference 0 reference 0 reference 0 reference RD/1AG-MM-GVH BM 1.35 ( ) ( ) < ( ) ( ) <01 RD/1AG-MM-GVH PB 1.95 ( ) < ( ) < ( ) < ( ) <01 *Other significant variables; none Other significant variables are the same as listed in Table 3, the analysis of grade III-IV acute GVHD. Other significant variables are the same as listed in Table 3, the analysis of chronic GVHD. ** Other significant variables are the same as listed in Table 3, the analysis of extensive chronic GVHD. Abbreviations: wotdep, without T cell depletion; wtdep, with T cell depletion. 4

5 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 5 Multivariate analysis of overall mortality, relapse, and non-relapse mortality Variable Overall mortality* Relapse Treatment-related mortality HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference 0 reference RD/1AG-MM-GVH wotdep 2 ( ) ( ) ( ) 02 RD/1AG-MM-GVH wtdep 0.71 ( 8-5 ) ( ) ( ) reference 0 reference 0 reference RD/1AG-MM-GVH BM 0.96 ( ) ( ) ( ) 29 RD/1AG-MM-GVH PB 1 ( ) ( 6-5 ) ( ) *Other significant variables are the same as listed in Table 2, the analysis of overall mortality. Other significant variables are the same as listed in Table 3, the analysis of relapse. Other significant variables are the same as listed in Table 3, the analysis of non-relapse mortality. 5

6 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 1. Acute and chronic GVHD according to the use of T cell depletion in the RD/1AG-MM-GVH group Supplemental Figure 2. Overall survival, relapse, and non-relapse mortality according to the stem cell source in the RD/1AG-MM-GVH group 6

7 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 1. grade II-IV acute GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep grade III-IV acute GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep Days after transplantation Days after transplantation C) D) chronic GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep extensive chronic GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep

8 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 2. Adjusted probability of overall survival relapse C) non-relapse mortality RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB